The mechanism of action of corticosteroids (deflazacort and prednisone), currently considered standard of care in DMD, is thought to be through inhibition of NF‐κB pathways in dystrophin‐deficient muscle. This evidence concerns the gene NFKB1 and Duchenne muscular dystrophy.